Selective Lentiviral Gene Delivery to CD133-Expressing Human Glioblastoma Stem Cells
Open Access
- 26 December 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (12) , e116114
Abstract
Glioblastoma multiforme (GBM) is a deadly primary brain malignancy. Glioblastoma stem cells (GSC), which have the ability to self-renew and differentiate into tumor lineages, are believed to cause tumor recurrence due to their resistance to current therapies. A subset of GSCs is marked by cell surface expression of CD133, a glycosylated pentaspan transmembrane protein. The study of CD133-expressing GSCs has been limited by the relative paucity of genetic tools that specifically target them. Here, we present CD133-LV, a lentiviral vector presenting a single chain antibody against CD133 on its envelope, as a vehicle for the selective transduction of CD133-expressing GSCs. We show that CD133-LV selectively transduces CD133+ human GSCs in dose-dependent manner and that transduced cells maintain their stem-like properties. The transduction efficiency of CD133-LV is reduced by an antibody that recognizes the same epitope on CD133 as the viral envelope and by shRNA-mediated knockdown of CD133. Conversely, the rate of transduction by CD133-LV is augmented by overexpression of CD133 in primary human GBM cultures. CD133-LV selectively transduces CD133-expressing cells in intracranial human GBM xenografts in NOD.SCID mice, but spares normal mouse brain tissue, neurons derived from human embryonic stem cells and primary human astrocytes. Our findings indicate that CD133-LV represents a novel tool for the selective genetic manipulation of CD133-expressing GSCs, and can be used to answer important questions about how these cells contribute to tumor biology and therapy resistance.Keywords
This publication has 43 references indexed in Scilit:
- LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virusProceedings of the National Academy of Sciences of the United States of America, 2013
- A restricted cell population propagates glioblastoma growth after chemotherapyNature, 2012
- Development of five new melanoma low passage cell lines representing the clinical and genetic profile of their tumors of originPigment Cell & Melanoma Research, 2012
- Haematopoietic stem cell differentiation promotes the release of prominin‐1/CD133‐containing membrane vesicles—a role of the endocytic–exocytic pathwayEMBO Molecular Medicine, 2011
- Loss of the Cholesterol-Binding Protein Prominin-1/CD133 Causes Disk Dysmorphogenesis and Photoreceptor DegenerationThe Journal of Neuroscience, 2009
- Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and AngiogenesisJournal of Clinical Oncology, 2008
- CD133 + neural stem cells in the ependyma of mammalian postnatal forebrainProceedings of the National Academy of Sciences, 2008
- Gene transfer in humans using a conditionally replicating lentiviral vectorProceedings of the National Academy of Sciences, 2006
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005